Mentioned On
Episode Mentions
Biotech Hangout · May 8, 2026
Episode 182 - May 8, 2026
“Approved Hunter syndrome drug based on heparin sulfate biomarker; FDA rejected neurofilament data as primary evidence”
Biotech Secondary Capital Raises and Market SaturationFDA Regulatory Uncertainty and Commissioner McCary LeadershipM&A Activity in Biotech and Venture Capital Returns
View Analysis